- Home
- TDUP vs GHRS Comparison
TDUP vs GHRS Comparison
Compare TDUP & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDUP
- GHRS
- Stock Information
- Founded
- TDUP 2009
- GHRS 2018
- Country
- TDUP United States
- GHRS Ireland
- Employees
- TDUP N/A
- GHRS N/A
- Industry
- TDUP Catalog/Specialty Distribution
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- TDUP Consumer Discretionary
- GHRS Health Care
- Exchange
- TDUP Nasdaq
- GHRS Nasdaq
- Market Cap
- TDUP 856.1M
- GHRS 849.8M
- IPO Year
- TDUP 2021
- GHRS 2021
- Fundamental
- Price
- TDUP $8.69
- GHRS $12.31
- Analyst Decision
- TDUP Buy
- GHRS Strong Buy
- Analyst Count
- TDUP 3
- GHRS 8
- Target Price
- TDUP $7.25
- GHRS $30.63
- AVG Volume (30 Days)
- TDUP 2.0M
- GHRS 187.6K
- Earning Date
- TDUP 08-04-2025
- GHRS 05-08-2025
- Dividend Yield
- TDUP N/A
- GHRS N/A
- EPS Growth
- TDUP N/A
- GHRS N/A
- EPS
- TDUP N/A
- GHRS N/A
- Revenue
- TDUP $266,789,000.00
- GHRS N/A
- Revenue This Year
- TDUP $10.87
- GHRS N/A
- Revenue Next Year
- TDUP $8.06
- GHRS N/A
- P/E Ratio
- TDUP N/A
- GHRS N/A
- Revenue Growth
- TDUP 7.96
- GHRS N/A
- 52 Week Low
- TDUP $0.50
- GHRS $6.00
- 52 Week High
- TDUP $8.75
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- TDUP 77.09
- GHRS 52.37
- Support Level
- TDUP $7.14
- GHRS $12.43
- Resistance Level
- TDUP $7.92
- GHRS $13.15
- Average True Range (ATR)
- TDUP 0.38
- GHRS 0.99
- MACD
- TDUP -0.01
- GHRS -0.14
- Stochastic Oscillator
- TDUP 97.14
- GHRS 41.03
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.